Background: Rotigotine is a novel non-ergot dopamine agonist, with effects on the biogenic amine neurotransmissions. For this reason we have used transdermal rotigotine in three congenital disorders of these neurotransmitters: Aromatic L-Aminoacid decarboxylase (AADC) deficiency (OMIM # 608643), Tyrosine hydroxilase (TH) deficiency (OMIM # 191290) and Dopamine transporter (DT) deficiency (OMIM # 126455). Case Report: In a 11 years old boy with AADC the replacement of pergolide with transdermal rotigotine resulted in an improvement of trunkal stability, head control and motor planning. A faster and more autonomous walking without support, a faster execution of motor tasks and an increase of muscular strength were observed. A similar improvement was also observed in a 15 years old male with TH deficiency. In this case the benefits were transitory and after some weeks a severe bradykinesia was observed. The discontinuation of rotigotine and its replacement with levo-dopa removed this last side effect. In a 4 years, 7 months old boy with a DT deficiency no clinical effects were obtained while bradykinesia , somnolence and asthenia. Conclusions: our experience suggests that transdermal rotigotine is a promising treatment in the therapeutic management of AADC deficiency. No results have been obtained in TH and DT deficiency.

TRANSDERMAL ROTIGOTINE AS A COMEDICATION IN THE TREATMENT OF CONGENITAL DISORDERS OF BIOGENIC AMINE / Mastrangelo, Mario; Galosi, Serena; Celato, Andrea; D'Agnano, Daniela; Giannini, Maria Teresa; S., Bertino; Leuzzi, Vincenzo. - In: JOURNAL OF INHERITED METABOLIC DISEASE. - ISSN 0141-8955. - STAMPA. - 35:1(2012), pp. S140-S140.

TRANSDERMAL ROTIGOTINE AS A COMEDICATION IN THE TREATMENT OF CONGENITAL DISORDERS OF BIOGENIC AMINE

MASTRANGELO, Mario;GALOSI, SERENA;CELATO, ANDREA;D'AGNANO, DANIELA;GIANNINI, Maria Teresa;LEUZZI, Vincenzo
2012

Abstract

Background: Rotigotine is a novel non-ergot dopamine agonist, with effects on the biogenic amine neurotransmissions. For this reason we have used transdermal rotigotine in three congenital disorders of these neurotransmitters: Aromatic L-Aminoacid decarboxylase (AADC) deficiency (OMIM # 608643), Tyrosine hydroxilase (TH) deficiency (OMIM # 191290) and Dopamine transporter (DT) deficiency (OMIM # 126455). Case Report: In a 11 years old boy with AADC the replacement of pergolide with transdermal rotigotine resulted in an improvement of trunkal stability, head control and motor planning. A faster and more autonomous walking without support, a faster execution of motor tasks and an increase of muscular strength were observed. A similar improvement was also observed in a 15 years old male with TH deficiency. In this case the benefits were transitory and after some weeks a severe bradykinesia was observed. The discontinuation of rotigotine and its replacement with levo-dopa removed this last side effect. In a 4 years, 7 months old boy with a DT deficiency no clinical effects were obtained while bradykinesia , somnolence and asthenia. Conclusions: our experience suggests that transdermal rotigotine is a promising treatment in the therapeutic management of AADC deficiency. No results have been obtained in TH and DT deficiency.
2012
04 Pubblicazione in atti di convegno::04d Abstract in atti di convegno
TRANSDERMAL ROTIGOTINE AS A COMEDICATION IN THE TREATMENT OF CONGENITAL DISORDERS OF BIOGENIC AMINE / Mastrangelo, Mario; Galosi, Serena; Celato, Andrea; D'Agnano, Daniela; Giannini, Maria Teresa; S., Bertino; Leuzzi, Vincenzo. - In: JOURNAL OF INHERITED METABOLIC DISEASE. - ISSN 0141-8955. - STAMPA. - 35:1(2012), pp. S140-S140.
File allegati a questo prodotto
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/481881
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus ND
  • ???jsp.display-item.citation.isi??? 0
social impact